Regeneron says Pasatru shows sustained efficacy and consistent safety from weeks 56 to 84
REGN•Regeneron said Pasatru showed sustained efficacy and a consistent, well-tolerated safety profile from weeks 56 to 84.
1. Pasatru results
Regeneron said Pasatru showed sustained efficacy and a consistent safety profile from weeks 56 to 84, with its safety profile remaining well tolerated through week 84.
